Search - tctmd.com

Displaying 221 - 240 of 532

Sort: Relevancy | Date

News Conference News TVT 2016

When Is Sick Too Sick for TAVR? Physicians Grapple With Identifying Futile Care

Michael O'Riordan

June 20, 2016

News Conference News TVT 2016

Teenage TAVR: Should Practice Forge on While Guidelines Grow Up?

Michael O'Riordan

June 20, 2016

News Conference News TVT 2016

Not All Valves With Leaflet Thickening Develop Mobility Problems, Repeat 4D CT Shows in SAVORY

Michael O'Riordan

June 18, 2016

Presentation TVT 2016

PARTNER Echocardiography Observations on Valve Durability

Presenter: Rebecca T. Hahn

June 17, 2016

News Conference News TVT 2016

What TAVR Needs Next . . . and What It’s Getting

Shelley Wood

June 17, 2016

News Features

Digesting the Valve Degeneration Data: One Month Later, Reactions From TAVR Experts Range From ‘Disturbed’ to Indifferent

Caitlin E. Cox

June 17, 2016

Presentation TVT 2016

Study Design for the PARTNER 3 Low-Risk Trial

Presenter: Martin B. Leon

June 16, 2016

Presentation TVT 2016

Highlights From PARTNER 2A in Intermediate-Risk Patients

Presenter: Michael J. Mack

June 16, 2016

News Daily News

大规模 Meta 分析显示，TAVR 与手术 30 天和 1 年死亡率相当

Michael O'Riordan

June 07, 2016

News Daily News

Según un Gran Meta Análisis Parecida Mortalidad al cabo de 30 Días y 1 Año con TAVR Versus Cirugía

Michael O'Riordan

June 07, 2016

News Daily News

More Proof of Declining Paravalvular Regurgitation With Newest Balloon-Expandable TAVR Devices

Shelley Wood

June 07, 2016

News Daily News

Equivalent Mortality at 30 Days and 1 Year With TAVR vs Surgery, Says Large Meta-analysis

Michael O'Riordan

June 07, 2016

News Conference News EuroPCR 2016

‘Obesity Paradox’ Alive, Well, and Mysterious After TAVR

Yael L. Maxwell

May 18, 2016

News Daily News

Patients With Low Aortic Valve Gradient May Be Less Likely to Reap TAVR’s Benefits

Todd Neale

May 16, 2016

News Daily News

房颤 TAVR 后相关死亡和出血风险增加

Michael O'Riordan

April 18, 2016

News Daily News

La FA Post-TAVR se Asocia a un Mayor Riesgo de Mortalidad y Hemorragias

Michael O'Riordan

April 18, 2016

News Daily News

A-fib Post-TAVR Associated With Increased Risk of Mortality, Bleeding

Michael O'Riordan

April 18, 2016

News Opinion Editor's Corner ACC 2016

Hot or Not, This Year’s Trials Offer Food for Thought: My Takeaways From ACC 2016

Shelley Wood

April 13, 2016

News Conference News ACC 2016

Self-Expanding Transcatheter Valve Maintains Advantage Over Surgery at 3 Years in High-Risk Elderly Patients

L.A. McKeown

April 04, 2016

News Conference News ACC 2016

Sapien 3 Superior to Surgery Among Intermediate-Risk Patients in Observational Trial

Yael L. Maxwell

April 03, 2016

Advertisement

When Is Sick Too Sick for TAVR? Physicians Grapple With Identifying Futile Care

Teenage TAVR: Should Practice Forge on While Guidelines Grow Up?

Not All Valves With Leaflet Thickening Develop Mobility Problems, Repeat 4D CT Shows in SAVORY

PARTNER Echocardiography Observations on Valve Durability

What TAVR Needs Next . . . and What It’s Getting

Digesting the Valve Degeneration Data: One Month Later, Reactions From TAVR Experts Range From ‘Disturbed’ to Indifferent

Study Design for the PARTNER 3 Low-Risk Trial

Highlights From PARTNER 2A in Intermediate-Risk Patients

大规模 Meta 分析显示，TAVR 与手术 30 天和 1 年死亡率相当

Según un Gran Meta Análisis Parecida Mortalidad al cabo de 30 Días y 1 Año con TAVR Versus Cirugía

More Proof of Declining Paravalvular Regurgitation With Newest Balloon-Expandable TAVR Devices

Equivalent Mortality at 30 Days and 1 Year With TAVR vs Surgery, Says Large Meta-analysis

‘Obesity Paradox’ Alive, Well, and Mysterious After TAVR

Patients With Low Aortic Valve Gradient May Be Less Likely to Reap TAVR’s Benefits

房颤 TAVR 后相关死亡和出血风险增加

La FA Post-TAVR se Asocia a un Mayor Riesgo de Mortalidad y Hemorragias

A-fib Post-TAVR Associated With Increased Risk of Mortality, Bleeding

Hot or Not, This Year’s Trials Offer Food for Thought: My Takeaways From ACC 2016

Self-Expanding Transcatheter Valve Maintains Advantage Over Surgery at 3 Years in High-Risk Elderly Patients

Sapien 3 Superior to Surgery Among Intermediate-Risk Patients in Observational Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content